Frankfurt - Delayed Quote EUR

LungLife AI, Inc. (9H4.F)

0.3280 0.0000 (0.00%)
At close: April 26 at 3:29 PM GMT+2

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Dr. Paul Pagano Ph.D. CEO, Chief Scientific Officer & Executive Director 295.12k -- 1985
Mr. David M. Anderson CFO, Company Secretary & Executive Director 222.6k -- 1963

LungLife AI, Inc.

2545 West Hillcrest Drive
Suite 140
Thousand Oaks, CA 91320
United States
805 409 9868 https://lunglifeai.com
Sector: 
Healthcare
Full Time Employees: 
15

Description

LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. It engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.

Corporate Governance

LungLife AI, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events